linrodostat (BMS-986205) / BMS, Ono Pharma 
Welcome,         Profile    Billing    Logout  
 0 Diseases   12 Trials   12 Trials   153 News 
7 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
linrodostat (BMS-986205) / BMS, Ono Pharma
ENERGIZE, NCT03661320 / 2017-004692-31: A Study to Compare Chemotherapy Alone Versus Chemotherapy Plus Nivolumab or Nivolumab and BMS-986205, Followed by Continued Therapy After Surgery With Nivolumab or Nivolumab and BMS-986205 in Participants With Muscle Invasive Bladder Cancer

Jan 2024 - Dec 2024: Data from CA 017-078 trial in combination with chemotherapy for muscle invasive urothelial cancer
Active, not recruiting
3
861
Europe, Canada, Japan, US, RoW
Nivolumab, Opdivo, BMS-936558, Gemcitabine, Chemotherapy, Cisplatin
Bristol-Myers Squibb, Ono Pharmaceutical Co. Ltd
Urinary Bladder Neoplasms, Muscle-Invasive Bladder Cancer
04/25
12/27
FRACTION-GC, NCT02935634 / 2016-002807-24: A Study to Test Combination Treatments in Participants With Advanced Gastric Cancer

Completed
2
190
Europe, Canada, US, RoW
Nivolumab, Opdivo, BMS-936558, Ipilimumab, Yervoy, BMS-734016, Relatlimab, BMS-986016, BMS-986205, Rucaparib, Rubraca
Bristol-Myers Squibb, Clovis Oncology, Inc.
Advanced Gastric Cancer
05/22
05/22
CA017-056, NCT04106414: Study of BMS-986205 and Nivolumab in Endometrial Cancer or Endometrial Carcinosarcoma That Has Not Responded to Treatment

Active, not recruiting
2
24
US
Nivolumab, BMS- 986205
Memorial Sloan Kettering Cancer Center, Bristol-Myers Squibb
Endometrial Adenocarcinoma, Endometrial Carcinosarcoma
09/25
09/25
NCT03854032: Nivolumab and BMS986205 in Treating Patients With Stage II-IV Squamous Cell Cancer of the Head and Neck

Active, not recruiting
2
45
US
Nivolumab, 946414-94-4, BMS-936558, MDX-1106, NIVO, ONO-4538, Opdivo, IDO1 Inhibitor BMS-986205, (R)-N-(4-chlorophenyl)-2-((1S,4S)-4-(6-fluoroquinolin-4-yl)cyclohexyl)propenamide, BMS 986205, BMS-986205, BMS986205, IDO-1 Inhibitor BMS-986205, Indoleamine-pyrrole 2,3-Dioxygenase Inhibitor BMS-986205, ONO-7701, Therapeutic Conventional Surgery, Questionnaire Administration
Thomas Jefferson University, Bristol-Myers Squibb
Lip, Oral Cavity Squamous Cell Carcinoma, Pharynx, Larynx, Squamous Cell Carcinoma
12/25
12/25
NCT03695250: BMS-986205 and Nivolumab as First or Second Line Therapy in Treating Patients With Liver Cancer

Terminated
1/2
8
US
IDO1 Inhibitor BMS-986205, BMS 986205, BMS-986205, BMS986205, IDO-1 Inhibitor BMS-986205, Indoleamine-pyrrole 2,3-Dioxygenase Inhibitor BMS-986205, ONO-7701, Nivolumab, BMS-936558, MDX-1106, NIVO, ONO-4538, Opdivo
Edward Kim, Bristol-Myers Squibb, National Cancer Institute (NCI)
Metastatic Hepatocellular Carcinoma, Stage III Hepatocellular Carcinoma AJCC v8, Stage IIIA Hepatocellular Carcinoma AJCC v8, Stage IIIB Hepatocellular Carcinoma AJCC v8, Stage IV Hepatocellular Carcinoma AJCC v8, Stage IVA Hepatocellular Carcinoma AJCC v8, Stage IVB Hepatocellular Carcinoma AJCC v8, Unresectable Hepatocellular Carcinoma
11/20
03/21
RELATIVITY-048, NCT03459222 / 2018-000058-22: An Investigational Study of Immunotherapy Combinations in Participants With Solid Cancers That Are Advanced or Have Spread

Active, not recruiting
1/2
255
Europe, US, RoW
Relatlimab, BMS-986016, Nivolumab, Opdivo, BMS-936558, BMS-986205, Linrodostat, Ipilimumab, Yervoy, BMS-734016
Bristol-Myers Squibb
Advanced Cancer
11/26
11/26
NCT04047706: Nivolumab, BMS-986205, and Radiation Therapy With or Without Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma

Active, not recruiting
1
18
US
IDO1 Inhibitor BMS-986205 25mg, BMS 986205, BMS-986205, BMS986205, IDO-1 Inhibitor BMS-986205, Indoleamine-pyrrole 2,3-Dioxygenase Inhibitor BMS-986205, ONO-7701, Nivolumab, BMS-936558, MDX-1106, NIVO, ONO-4538, Opdivo, Radiation Therapy, Cancer Radiotherapy, Irradiate, Irradiated, irradiation, Radiation, Radiotherapeutics, RADIOTHERAPY, RT, Therapy, Radiation, Temozolomide, CCRG-81045, Imidazo[5,1-d]-1,2,3,5-tetrazine-8-carboxamide, 3, 4-dihydro-3-methyl-4-oxo-, M & B 39831, M and B 39831, Methazolastone, RP-46161, SCH 52365, Temcad, Temodal, Temodar, Temomedac, TMZ, IDO1 Inhibitor BMS-986205 50 mg, IDO1 Inhibitor BMS-986205 100 mg
Northwestern University, National Cancer Institute (NCI)
Glioblastoma
02/25
06/27

Download Options